Baseline characteristics
| Nintedanib (n=26) | Placebo (n=13) | |
| Female | 16 (61.5) | 8 (61.5) |
| Age, years | 12.5±3.6 | 12.9±2.8 |
| Age categories | ||
| 6– <12 years | 8 (30.8) | 4 (30.8) |
| 12– <18 years | 18 (69.2) | 9 (69.2) |
| Height, cm | 147.0±16.9 | 148.4±16.3 |
| Weight, kg | 40.9±16.0 | 44.7±21.5 |
| Weight categories | ||
| 13.5– <23 kg | 5 (19.2) | 3 (23.1) |
| 23– <33.5 kg | 2 (7.7) | 3 (23.1) |
| 33.5– <57.5 kg | 18 (69.2) | 3 (23.1) |
| 57.5 kg | 1 (3.8) | 4 (30.8) |
| Race | ||
| White | 19 (73.1) | 12 (92.3) |
| Black or African American | 3 (11.5) | 0 |
| Asian | 2 (7.7) | 0 |
| Other/missing | 2 (7.7) | 1 (7.7) |
| Time since diagnosis of ILD, years | 5.0±4.5 | 7.1±5.2 |
| Diagnosis | ||
| Surfactant protein deficiency | 7 (26.9) | 5 (38.5) |
| Systemic sclerosis | 4 (15.4) | 3 (23.1) |
| Toxic/radiation/drug-induced pneumonitis | 3 (11.5) | 1 (7.7) |
| Chronic hypersensitivity pneumonitis | 2 (7.7) | 0 |
| Other (diagnoses made in one patient) | 10 (38.5) | 4 (30.8) |
| FVC, mL | 1633±914 | 1932±991 |
| FVC % pred | 57.7±21.8 | 62.9±22.6 |
| FVC z-score# | −3.6±1.9 | −3.2±1.9 |
| DLCO % pred¶ | 52.9±26.7 | 63.1±10.7 |
Data are presented as n (%) or mean±sd. ILD: interstitial lung disease; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide. #: the z-score gives the number of standard deviations a certain value deviates from the mean value of a reference population; ¶: corrected for haemoglobin (n=18 in the nintedanib group and n=9 in the placebo group).